Clinical efficacy and related mechanism of Edaravone and dexborneol in the treatment of newly diagnosed untreated Parkinson's disease patients

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200056774

Enrollment

Unknown

Registered

2022-02-15

Start date

2022-03-01

Completion date

Unknown

Last updated

2023-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

parkinson’s disease

Interventions

patient group:Edaravone and dexborneol

Healthy control group:Nil

Eligibility

Sex/Gender

All

Age

30 Years to 75 Years

Inclusion criteria

Inclusion criteria: The subjects were mainly from the PD Clinic of the Affiliated Brain Hospital of Nanjing Medical University. They were 30-75 years old at the time of enrollment, with normal vision or corrected vision, normal hearing in both ears, and all were right-handed. Inclusion criteria for PD patients: ?Diagnostic criteria for PD patients meet the 2015 MDS diagnosis criteria for PD; ?Have not taken any anti-PD drugs at the first visit; ?HAMD=8 points.

Exclusion criteria

Exclusion criteria: Exclusion criteria: ?History of consciousness disturbance; ?Family genetic diseases; ?Central nervous system infection, head injury, epilepsy, multiple sclerosis, toxic metabolic diseases, intracranial tumors, hypothyroidism, diabetes and other physical diseases; ?Schizophrenia History of mental illness, manic episode, bipolar disorder, personality change, etc.; ?Have history of alcohol/drug dependence or taking related drugs to improve cognition; ?Combined with serious heart, liver, kidney, brain and hematopoietic diseases; ?Electronics It is contraindicated with MRI scans such as metal device implantation; ?Have a history of electric convulsions; ?T2-weighted MRI shows cerebral infarction or vascular injury; ?Allergy to edaravone dexkanol.

Design outcomes

Primary

Measure	Time frame
UNIFIED PARKINSON'S DISEASE RATING SCALE;Hamilton Depression Scale;	—

Secondary

Measure	Time frame
Clinical Global Impression Improvement, CGI-I;PD questionnaire 39 dimensions,PDQ-39;Hamilton Anxiey Scale;Montreal Cognitive Assessment;Mini-Mental State Examination;Parkinson's disease non-motor symptom scale;Blood inflammatory mediators;Functional magnetic resonance imaging data;Magnetoencephalogram data;electroencephalogram data;	—

Countries

China

Contacts

Public ContactWeiguo Liu

liuweiguo1111@sina.com13914725569

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026